Loading…
Employees: 63
Size BlossomHill Therapeutics (BLSM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $429M, the 2803rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.50 on 6 Nov 2026.
Short interest Short interest is 1.5% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$441,000 | -$350,000 |
| EBITDA | n/a | -$63.6M | -$36.1M |
| Net income | n/a | -$60.6M | -$30.7M |
| Free cash flow | n/a | -$48.0M | -$31.5M |
| Capital expenditure | n/a | $1.07M | $92,000 |
| Total debt | $280M | $279M | $173M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLSM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.0% | -11.1% | 3rd lowest of 21 |
| Distance from 52-week high | -51.8% | -31.4% | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | 7.0× | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 2.0× | 9.9% | +6.7% |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 1.6× | 19.7% | +3.5% |
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 2.9× | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | 5.7× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 1.5× | 2.8% | +0.3% |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 0.7× | -8.8% | +12.8% |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | 2.5× | 6.5% | +15.3% |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | 1.3× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 3.5× | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 2.4× | -4.5% | +12.1% |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | 5.8× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | 1.6× | -0.4% | +11.2% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | 23.7× | n/a | n/a |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 1.8× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | 4.3× | 23.7% | +28.2% |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | 6.0× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | 10.5× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | 4.4× | n/a | n/a |